Enhancing the role of UK medicine regulation

We were delighted to act as research partners for a new report authored by the Association of the British Pharmaceutical Industry (ABPI). ‘Enhancing the role of UK medicine regulation’ explores the crucial role of regulatory excellence in driving innovation and early access, supporting patient trust, and attracting investment into the UK, as covered in the Financial Times.

Drawing on evidence from the life sciences community, the report sets out key recommendations in the following areas to rebuild the UK’s world-class reputation in regulatory science, medicines’ development and licensing:

• Enhancing communications, transparency, and accountability.
• Improving resourcing and expertise to support its regulatory functions.
• Strengthening the regulatory framework with flexible licensing routes, expedited clinical trial approvals and horizon scanning capabilities.

These recommendations are designed to support the government’s ambitions for economic growth, ensuring earlier patient access to innovative treatments, while also driving inward investment into the UK life sciences ecosystem.

Stephen Adams, GC Senior Director, said:

“The question of how to renew the operating capabilities of the MHRA is a once-in-a-generation regulatory policy challenge for life sciences in UK. GC was delighted to be asked to partner with the ABPI in producing a robust evidence base for both a clear diagnostic and a set of practical and realistic recommendations. Our consultant team was able to work alongside ABPI and UK sectoral experts to bring UK and international regulatory expertise and effective survey and stakeholder engagement techniques. The resulting report is a model of its kind”.